RPAM
LXRX icon

Rhenman & Partners Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200,000
Closed -$2.15M – 97
2015
Q3 		$2.15M Buy
200,000
+29,085
+17% +$318K 0.34% 77
2015
Q2 		$1.38M Sell
170,915
-56,914
-25% -$418K 0.19% 93
2015
Q1 		$1.51M Hold
227,829
– – 0.27% 85
2014
Q4 		$1.45M Buy
227,829
+185,714
+441% +$1.5M 0.42% 78
2014
Q3 		$416K Hold
42,115
– – 0.13% 97
2014
Q2 		$475K Hold
42,115
– – 0.14% 94
2014
Q1 		$510K Sell
42,115
-742
-2% -$9.48K 0.16% 90
2013
Q4 		$540K Buy
+42,857
New +$682K 0.22% 80

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return